530 related articles for article (PubMed ID: 19536023)
21. Do drug formulary policies reflect evidence of value?
Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
[TBL] [Abstract][Full Text] [Related]
22. Trends in the measurement of health utilities in published cost-utility analyses.
Brauer CA; Rosen AB; Greenberg D; Neumann PJ
Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
[TBL] [Abstract][Full Text] [Related]
23. Trends in cost effectiveness analyses in orthopaedic surgery.
Brauer CA; Neumann PJ; Rosen AB
Clin Orthop Relat Res; 2007 Apr; 457():42-8. PubMed ID: 17242614
[TBL] [Abstract][Full Text] [Related]
24. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches.
Clement Nee Shrive FM; Ghali WA; Donaldson C; Manns BJ
Health Econ; 2009 Apr; 18(4):377-88. PubMed ID: 18615835
[TBL] [Abstract][Full Text] [Related]
25. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
Birch S; Gafni A
J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
[TBL] [Abstract][Full Text] [Related]
26. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
Nicholson A; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Schramm W; van Hout BA; Willan AR; Feldman BM
Haemophilia; 2008 Jan; 14(1):127-32. PubMed ID: 18005148
[TBL] [Abstract][Full Text] [Related]
27. Health-related quality of life after stroke: review of the literature and implications for future research.
Tseng MC; Lin HJ
Acta Neurol Taiwan; 2007 Mar; 16(1):7-12. PubMed ID: 17486727
[TBL] [Abstract][Full Text] [Related]
28. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
[TBL] [Abstract][Full Text] [Related]
29. [How are quality-adjusted life years defined in German studies?].
Schwappach DL; Boluarte TA
Dtsch Med Wochenschr; 2006 Sep; 131(37):2004-9. PubMed ID: 16960766
[TBL] [Abstract][Full Text] [Related]
30. Quality-adjusted life years: how useful in medico economic studies.
Brauer CA; Neumann PJ
Fundam Clin Pharmacol; 2005 Dec; 19(6):603-7. PubMed ID: 16313271
[TBL] [Abstract][Full Text] [Related]
31. Variations in cost calculations in spine surgery cost-effectiveness research.
Alvin MD; Miller JA; Lubelski D; Rosenbaum BP; Abdullah KG; Whitmore RG; Benzel EC; Mroz TE
Neurosurg Focus; 2014 Jun; 36(6):E1. PubMed ID: 24881633
[TBL] [Abstract][Full Text] [Related]
32. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
Nelson CL; Sun JL; Tsiatis AA; Mark DB
Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
[TBL] [Abstract][Full Text] [Related]
33. The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery.
Blough DK; Ramsey S; Sullivan SD; Yusen R;
Health Econ; 2009 Jan; 18(1):91-101. PubMed ID: 18435426
[TBL] [Abstract][Full Text] [Related]
34. Economic appraisal of the Boston Ocular Surface Prosthesis.
Shepard DS; Razavi M; Stason WB; Jacobs DS; Suaya JA; Cohen M; Rosenthal P
Am J Ophthalmol; 2009 Dec; 148(6):860-8.e2. PubMed ID: 19781684
[TBL] [Abstract][Full Text] [Related]
35. Patient adherence: a blind spot in cost-effectiveness analyses?
Rosen AB; Spaulding AB; Greenberg D; Palmer JA; Neumann PJ
Am J Manag Care; 2009 Sep; 15(9):626-32. PubMed ID: 19747027
[TBL] [Abstract][Full Text] [Related]
36. Growth and quality of the cost-utility literature, 1976-2001.
Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
[TBL] [Abstract][Full Text] [Related]
37. Quality assessment of published health economic analyses from South America.
Machado M; Iskedjian M; Einarson TR
Ann Pharmacother; 2006 May; 40(5):943-9. PubMed ID: 16670369
[TBL] [Abstract][Full Text] [Related]
38. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
Gafni A; Birch S
Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
[TBL] [Abstract][Full Text] [Related]
39. Costing methodology in laparoscopic surgery.
Kesteloot K; Demoulin L; Penninckx F
Acta Chir Belg; 1996; 96(6):252-60. PubMed ID: 9008765
[TBL] [Abstract][Full Text] [Related]
40. How to measure the cost-effectiveness of periodontal treatments.
Vernazza C; Heasman P; Gaunt F; Pennington M
Periodontol 2000; 2012 Oct; 60(1):138-46. PubMed ID: 22909111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
